Skip to content
Clinical Trials – home

Dermatophagoides Farinae: A Comprehensive Guide for Patients

3 / 5
trials open to patients / all trials
7+
Countries

In short

This article discusses recent clinical trials investigating the use of Dermatophagoides Farinae (house dust mite) extract in treating allergic asthma and rhinitis. These studies aim to evaluate the safety and effectiveness of various treatments, including allergen immunotherapy and novel anti-inflammatory drugs, in managing allergic reactions to house dust mites. The trials focus on different aspects of allergic responses, such as airway inflammation, lung function, and immune system activity.

At a glance

Main Focus
Evaluation of treatments for allergic asthma and rhinitis caused by Dermatophagoides Farinae (house dust mite)
Key Treatments
Anakinra (IL-1 blocker), Allergen immunotherapy using Dermatophagoides Farinae extract
Primary Outcomes
Changes in lung function (FEV1), airway inflammation, safety and tolerability of treatments
Secondary Outcomes
Mucociliary clearance, sputum composition, airway hyper-responsiveness, biomarkers of inflammation
Study Designs
Randomized, double-blind, placebo-controlled trials with crossover or parallel group designs
Patient Population
Adults with mild allergic asthma or allergic rhinitis sensitized to Dermatophagoides Farinae
Safety Assessments
Vital signs, physical examinations, blood tests, electrocardiograms, adverse event monitoring

What is Dermatophagoides Farinae?

Dermatophagoides Farinae, also known as house dust mite allergen extract, is a substance used in the treatment of allergies. It is derived from a specific species of dust mite, which is a common cause of allergies in many people. This extract is used both as a diagnostic tool and as a treatment for allergic conditions, particularly those related to dust mite allergies.

Conditions Treated

Dermatophagoides Farinae is primarily used to treat the following conditions:

  • Allergic Asthma: A type of asthma triggered by allergens, in this case, dust mites.
  • Allergic Rhinitis: Also known as hay fever, this condition causes symptoms like sneezing, runny nose, and itchy eyes when exposed to allergens.
  • House Dust Mite Rhinitis: A specific form of allergic rhinitis caused by dust mites.

How It Works

Dermatophagoides Farinae works through a process called immunotherapy. Here's a simplified explanation of how it functions:

  1. Exposure: The patient is exposed to small, controlled amounts of the allergen (dust mite extract).
  2. Immune Response: This exposure triggers the immune system to respond.
  3. Desensitization: Over time, the immune system becomes less sensitive to the allergen.
  4. Tolerance: Eventually, the body develops a tolerance, reducing allergic reactions when exposed to dust mites in everyday life.

Administration and Dosage

Dermatophagoides Farinae is typically administered in the following ways:

  • Inhalation: In some clinical trials, it is given as an inhaled allergen challenge.
  • Subcutaneous Injection: It can be injected under the skin in gradually increasing doses.

The dosage varies depending on the specific treatment protocol. For example, in one study, the extract was standardized at 30,000 allergen units (AU)/mL. In another study, doses ranged from 100 PAU (Protein Allergen Units) to 800 PAU, with a gradual increase over several weeks.

Clinical Trials and Research

Several clinical trials are investigating the effectiveness of Dermatophagoides Farinae in treating allergic conditions:

  • A study examining its use as a rescue treatment for allergic airway inflammation.
  • Research on its effectiveness when administered during different phases of an allergic response.
  • A trial comparing different doses to evaluate safety and immune-stimulating efficacy.

Potential Side Effects

As with any medical treatment, Dermatophagoides Farinae may cause side effects. Researchers carefully monitor for:

  • Local reactions: Such as redness or swelling at the injection site.
  • Systemic reactions: These are whole-body responses, which can range from mild to severe.
  • Changes in lung function: Measured by tests like FEV1 (Forced Expiratory Volume in 1 second).
  • Changes in airway inflammation: Monitored through various tests including sputum analysis and exhaled nitric oxide levels.

Important Considerations

When considering treatment with Dermatophagoides Farinae, keep in mind:

  • It's typically used for people with confirmed dust mite allergies.
  • Treatment is usually long-term, often lasting several months to years.
  • Regular follow-ups with your allergist are crucial to monitor progress and adjust treatment as needed.
  • This treatment aims to reduce symptoms and improve quality of life, but it may not completely cure the allergy.

Always consult with a healthcare professional before starting any new treatment, as they can provide personalized advice based on your specific health situation.

Questions people often ask

Conditions where Dermatophagoides Farinae is being studied

Each condition opens its own overview and trial list

Trials with Dermatophagoides Farinae

Recruiting trials first

See all 5 →
Quick filters
  • Participants:All ages
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).